Chen Jin-Bor, Chang Chiung-Chih, Moi Sin-Hua, Li Lung-Chih
Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and School of Medicine, Kaohsiung, 833, Taiwan, Republic of China.
College of Medicine, Chang Gung University, Taoyuan, 330, Taiwan, Republic of China.
Int J Gen Med. 2022 Jul 11;15:6115-6125. doi: 10.2147/IJGM.S368987. eCollection 2022.
This study aimed to compare the plasma levels of nanoparticle-based neurodegenerative biomarkers between hemodialysis (HD) participants with grossly normal cognitive function and healthy controls.
A cohort of participants undergoing maintenance HD and healthy controls were enrolled for comparison between July and October 2021. The immunomagnetic reduction method was used to measure plasma neurodegenerative biomarkers Aβ Aβ tau protein, and neurofilament light chain (NfL). The clinical dementia rating (CDR) was used to evaluate cognitive function. A receiver operating characteristic curve was used to discriminate between HD participants and healthy controls.
There were 52 and 18 participants in the HD and healthy control groups, respectively. The mean age of the HD participants was 62 years, and that of the healthy controls was 57 years. The mean HD vintage in the HD cohort was 11.8 years. HD participants demonstrated significantly higher plasma levels of Aβ tau protein, Aβ × tau, and NfL and Aβ/Aβ ratio and significantly lower plasma Aβ levels than healthy controls. The measured plasma biomarkers could not discriminate between CDR0 and CDR0.5 HD participants. The area under the curve of the study biomarkers to discriminate HD participants from healthy controls ranged from 0.987 (Aβ × tau) to 0.889 (NfL).
The plasma levels of nanoparticle-based neurodegenerative biomarkers were higher in HD participants with grossly normal cognitive function than in healthy controls. These findings imply that neurodegenerative changes appear in HD participants. A profile of plasma neurodegenerative biomarkers could be considered a potential surrogate for evaluating long-term cognitive function in HD participants.
本研究旨在比较认知功能大体正常的血液透析（HD）参与者与健康对照者之间基于纳米颗粒的神经退行性生物标志物的血浆水平。
2021年7月至10月招募了一组接受维持性HD的参与者和健康对照者进行比较。采用免疫磁珠法测量血浆神经退行性生物标志物Aβ、Aβ tau蛋白和神经丝轻链（NfL）。使用临床痴呆评定量表（CDR）评估认知功能。采用受试者工作特征曲线区分HD参与者和健康对照者。
HD组和健康对照组分别有52名和18名参与者。HD参与者的平均年龄为62岁，健康对照者的平均年龄为57岁。HD队列中的平均HD病程为11.8年。与健康对照者相比，HD参与者的血浆Aβ tau蛋白、Aβ×tau和NfL水平以及Aβ/Aβ比值显著更高，而血浆Aβ水平显著更低。所测量的血浆生物标志物无法区分CDR0和CDR0.5的HD参与者。研究生物标志物区分HD参与者和健康对照者的曲线下面积范围为0.987（Aβ×tau）至0.889（NfL）。
认知功能大体正常的HD参与者中基于纳米颗粒的神经退行性生物标志物的血浆水平高于健康对照者。这些发现表明HD参与者出现了神经退行性变化。血浆神经退行性生物标志物谱可被视为评估HD参与者长期认知功能的潜在替代指标。
